Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes

NCT01591902 is registered in ClinicalTrials.gov with Theratechnologies as lead sponsor.

NCT NCT01591902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01591902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Lead sponsor
Theratechnologies
Phase
Phase 4
Overall status
Terminated
Start date
June 30, 2012
Completion date
August 31, 2018
Enrollment
129 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic retinopathy, hiv